November 10, 2026 results are next for MaxCyte stock

Published on 10/15/2026 at 19:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter core revenue reached USD 8.10 million, up 26.00 percent. MaxCyte stock costs EUR 1.15 on October 15, 2026, up 3.20 percent on Nasdaq.

Results date and valuation

MaxCyte's earnings call is scheduled for November 10, 2026.
Third-quarter core revenue reached USD 8.10 million, up 26.00 percent year over year.
MaxCyte stock costs EUR 1.15 at Lang & Schwarz on October 15, 2026 at 7:13 p.m. CEST, 3.20 percent above the Nasdaq prior close of October 14, 2026.
MaxCyte's market capitalization was USD 133.3 million on October 15, 2026.

MXCT, US57777K1060, Illustration mit AI erstellt.

MaxCyte's earnings call is scheduled for November 10, 2026, according to GlobeNewswire. At Lang & Schwarz, the stock was quoted at EUR 1.15 on October 15, 2026 at 7:13 p.m. CEST.

Core revenue reached USD 8.10 million

MaxCyte reported preliminary core business revenue of USD 8.10 million for the third quarter of 2026, up 26.00 percent from the third quarter of 2025. The figure excludes royalty revenue that will be reported with the full results. The company also recorded more than USD 1.00 million in Strategic Platform License program-related revenue, including a USD 1.00 million milestone payment, according to GlobeNewswire.

USD 0.64 to USD 1.87 range

The Nasdaq quote stood at USD 1.29 at 1:20 p.m. ET on October 15, 2026, up 3.20 percent from the USD 1.25 prior close. The session range was USD 1.25 to USD 1.30, while the 52-week range was USD 0.64 to USD 1.87. Volume reached 1,252,658 shares against an average of 779,935 shares.

The euro quote and the Nasdaq quote reflect different venues and currencies. The market move therefore belongs to the Nasdaq comparison, while the Lang & Schwarz figure remains the German trading reference for readers using euros.

Valuation and November 10 date

MaxCyte's market capitalization was USD 133.3 million on October 15, 2026. The reported trailing P/E ratio was minus 3.84 and the dividend yield was 0.00 percent. The November 10, 2026 earnings call will provide the full third-quarter results, including royalty revenue, after the preliminary figures released on October 14, 2026.

Comparison with peers

MaxCyte (Nasdaq, USD): plus 3.30 percent, P/E minus 3.84, market capitalization USD 133.3 million.

Editas Medicine (Nasdaq, USD): plus 5.35 percent, P/E minus 3.20, market capitalization USD 367.3 million.

CRISPR Therapeutics (Nasdaq, USD): plus 2.56 percent, P/E minus 10.82, market capitalization USD 5.0 billion.

Evening euro quote

The Nasdaq price places MaxCyte above its October 14, 2026 close, while the stock remains below its 52-week high of USD 1.87. The next scheduled earnings event is November 10, 2026.

MaxCyte's cell-engineering platform supplies instruments, processing assemblies and software for research, gene editing, bioprocessing and cell therapy applications.

The further course of trading is shown by the continuously updated real-time quote of MaxCyte stock.